SEQUENT SCIENTIFIC share price has zoomed 5% and is presently trading at Rs 172.8.
Meanwhile, the BSE HEALTHCARE index is at 42,998.1 (down 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 3.1%) and MAX HEALTHCARE INSTITUTE (up 2.1%).
Glenmark Pharma (down 3.5%) and Dr. Reddys (down 3.2%) are among the top losers today.
Over the last one year, SEQUENT SCIENTIFIC has moved up from Rs 99.7 to Rs 172.8, registering a gain of Rs 73.1 (up 73.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,318.2 to 42,998.1, registering a gain of 57.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 225.9%), Glenmark Pharma (up 120.2%) and SUVEN PHARMACEUTICALS (up 118.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,893.7 (down 0.1%).
The top losers among the BSE Sensex today are Tata Motors (down 3.7%) and Maruti Suzuki (down 1.9%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.
In the meantime, NSE Nifty is at 24,285.9 (down 0.2%). Tata Motors and IOC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,049.1 to 79,893.7, registering a gain of 15,844.7 points (up 24.7%).
SEQUENT SCIENTIFIC net profit grew 126.1% YoY to Rs 91 million for the quarter ended June 2024, compared to a loss of Rs 347 million a year ago. Net sales rose 17.1% to Rs 3,902 million during the period as against Rs 3,332 million in April-June 2023.
For the year ended March 2024, SEQUENT SCIENTIFIC reported 75.7% increase in net profit to Rs -296 million compared to net loss of Rs 1,220 million during FY23. Revenue of the company fell 3.6% to Rs 13,697 million during FY24.
The current Price to earnings ratio of SEQUENT SCIENTIFIC, based on rolling 12 month earnings, stands at 305.3.
Equitymaster requests your view! Post a comment on "SEQUENT SCIENTIFIC Gains 5%; BSE HEALTHCARE Index Down 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!